GT201200153A - Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos - Google Patents
Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedososInfo
- Publication number
- GT201200153A GT201200153A GT201200153A GT201200153A GT201200153A GT 201200153 A GT201200153 A GT 201200153A GT 201200153 A GT201200153 A GT 201200153A GT 201200153 A GT201200153 A GT 201200153A GT 201200153 A GT201200153 A GT 201200153A
- Authority
- GT
- Guatemala
- Prior art keywords
- novedous
- carbamoil
- derivatives
- amino
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS NOVEDOSOS QUE SON ÚTILES COMO INHIBIDORES DE LA ENDOPEPTIDASA NEUTRA, POR EJEMPLO, COMO INHIBIDORES DE LA ENZIMA DEGRADANTE DEL FACTOR NATRIURÉTICO AURICULAR (ANF) EN LOS MAMÍFEROS, PARA PROLONGAR Y POTENCIAR LAS PROPIEDADES DIURÉTICAS, NATRIURÉTICAS Y VASODILATADORAS DEL ANF
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26313709P | 2009-11-20 | 2009-11-20 | |
US35991410P | 2010-06-30 | 2010-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201200153A true GT201200153A (es) | 2014-12-30 |
Family
ID=43431937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201200153A GT201200153A (es) | 2009-11-20 | 2012-05-18 | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos |
Country Status (37)
Country | Link |
---|---|
US (4) | US8222286B2 (es) |
EP (2) | EP2735561B1 (es) |
JP (2) | JP5543609B2 (es) |
KR (1) | KR101460421B1 (es) |
CN (1) | CN102666493B (es) |
AR (1) | AR079061A1 (es) |
AU (1) | AU2010320930B2 (es) |
BR (1) | BR112012011977A2 (es) |
CA (1) | CA2780150C (es) |
CL (1) | CL2012001298A1 (es) |
CO (1) | CO6540001A2 (es) |
CR (1) | CR20120237A (es) |
DK (1) | DK2501683T3 (es) |
EA (1) | EA021479B1 (es) |
EC (1) | ECSP12011978A (es) |
ES (2) | ES2598961T3 (es) |
GT (1) | GT201200153A (es) |
HK (1) | HK1170475A1 (es) |
HN (1) | HN2012001037A (es) |
HR (1) | HRP20140691T1 (es) |
IL (1) | IL219314A0 (es) |
IN (1) | IN2012DN02465A (es) |
JO (1) | JO2967B1 (es) |
MA (1) | MA33886B1 (es) |
MX (1) | MX2012005813A (es) |
MY (1) | MY158299A (es) |
NZ (1) | NZ599136A (es) |
PE (1) | PE20121311A1 (es) |
PL (1) | PL2501683T3 (es) |
PT (1) | PT2501683E (es) |
RS (1) | RS53422B (es) |
SI (1) | SI2501683T1 (es) |
TN (1) | TN2012000125A1 (es) |
TW (1) | TWI481598B (es) |
UY (1) | UY33044A (es) |
WO (1) | WO2011061271A1 (es) |
ZA (1) | ZA201202018B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2602826T3 (es) | 2009-05-28 | 2017-02-22 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
MA33364B1 (fr) * | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8993631B2 (en) * | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
NZ611528A (en) | 2010-12-15 | 2015-06-26 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
ME02295B (me) | 2010-12-15 | 2016-02-20 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
CA2825737C (en) | 2011-02-17 | 2018-11-13 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
ES2564275T3 (es) | 2011-02-17 | 2016-03-21 | Theravance Biopharma R&D Ip, Llc | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
ES2653215T3 (es) | 2011-05-31 | 2018-02-06 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
CN103582630B (zh) | 2011-05-31 | 2016-08-17 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
CA2835281A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
CA2871292A1 (en) | 2012-05-31 | 2013-12-05 | Theravance Biopharma R&D Ip, Llc | Nitric oxide donor neprilysin inhibitors |
RS55967B1 (sr) | 2012-06-08 | 2017-09-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
EP2858650B1 (en) | 2012-06-08 | 2018-11-14 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
BR112015002821B1 (pt) | 2012-08-08 | 2022-10-18 | Theravance Biopharma R&D Ip, Llc | Compostos inibidores de neprilisina e composição farmacêutica |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
AP2015008621A0 (en) * | 2013-02-14 | 2015-07-31 | Novartis Ag | Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors |
WO2014126972A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
RS56300B1 (sr) | 2013-03-05 | 2017-12-29 | Theravance Biopharma R&D Ip Llc | Inhibitori neprilizina |
JP2016527249A (ja) | 2013-07-25 | 2016-09-08 | ノバルティス アーゲー | 合成アペリンポリペプチドのバイオコンジュゲート |
UY35670A (es) | 2013-07-25 | 2015-02-27 | Novartis Ag | Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca |
ES2718239T3 (es) | 2014-01-30 | 2019-06-28 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina |
SG11201606057PA (en) | 2014-01-30 | 2016-08-30 | Theravance Biopharma R&D Ip Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
KR20170103970A (ko) | 2015-01-23 | 2017-09-13 | 노파르티스 아게 | 개선된 반감기를 갖는 합성 아펠린 지방산 접합체 |
ES2923002T3 (es) | 2015-02-11 | 2022-09-22 | Theravance Biopharma R&D Ip Llc | Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina |
RS61325B1 (sr) | 2015-02-19 | 2021-02-26 | Theravance Biopharma R&D Ip Llc | (2r,4r)-5-(5'-hloro-2'-fluorobifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina |
HUE055546T2 (hu) | 2016-03-08 | 2021-12-28 | Theravance Biopharma R&D Ip Llc | Kristályos (2S,4R)-5-(5'-klór-2-fluor-[1,1'-bifenil]-4-il)-2-(etoximetil)-4-(3-hidroxi izoxazol-5-karboxamido)-2-metilpentánsav és alkalmazásaik |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状五聚体化合物 |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
JP2022509184A (ja) | 2018-11-27 | 2022-01-20 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド |
WO2020254553A1 (en) | 2019-06-19 | 2020-12-24 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
Family Cites Families (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1194593B (it) | 1978-11-25 | 1988-09-22 | Nippon Kayaku Kk | Procedimento per la produzione di acidi treo-3-ammino-2-idrossibutanoilamminoacetici nonche' di loro intermedi |
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
EP0038046B1 (en) | 1980-04-11 | 1984-02-29 | The Wellcome Foundation Limited | Pharmaceutical amides, and preparation, formulations and use thereof |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4610816A (en) | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
US4721726A (en) | 1980-12-18 | 1988-01-26 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
IE53315B1 (en) * | 1980-12-18 | 1988-10-12 | Schering Corp | Substituted dipeptides,processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase |
JPS5865260A (ja) | 1981-10-13 | 1983-04-18 | Microbial Chem Res Found | 3−アミノ−2−ヒドロキシ−4−フエニル酪酸誘導体および医薬組成物 |
FR2518088B1 (fr) | 1981-12-16 | 1987-11-27 | Roques Bernard | Nouveaux derives d'aminoacides, et leur application therapeutique |
NZ201001A (en) * | 1982-06-17 | 1986-02-21 | Schering Corp | Substituted dipeptide derivatives and method of preparation |
DE3376649D1 (en) | 1982-06-17 | 1988-06-23 | Schering Corp | Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
DK31784A (da) | 1983-01-28 | 1984-07-29 | Schering Corp | Phosphorholdige amidforbindelser, farmaceutiske kompositioner indeholdende disse, og fremgangsmaader til forbindelsernes fremstilling |
US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
EP0136883B1 (en) | 1983-10-03 | 1987-11-25 | E.R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPS60248659A (ja) | 1984-05-25 | 1985-12-09 | Microbial Chem Res Found | 3−〔n−(メルカプトアシル)〕アミノ−4−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤 |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
FR2597865B1 (fr) | 1986-04-29 | 1990-11-09 | Roussel Uclaf | Nouveaux derives d'un acide benzyl alkyl carboxylique substitue par un radical 4-pyridinyl aminocarbonyle, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
FR2605004B1 (fr) | 1986-09-25 | 1989-01-13 | Centre Nat Rech Scient | Nouveaux derives d'amino-acides, leur procede de preparation et composition pharmaceutiques les contenant |
CA1337400C (en) | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
EP0429537A4 (en) | 1988-08-18 | 1991-08-21 | California Biotechnology, Inc. | Atrial natriuretic peptide clearance inhibitors |
FR2651229B1 (fr) | 1989-08-24 | 1991-12-13 | Inst Nat Sante Rech Med | Nouveaux derives d'amino-acides, leur procede de preparation et leur application therapeutique. |
FR2652087B1 (fr) * | 1989-09-15 | 1993-10-15 | Bioprojet Ste Civile | Derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques. |
WO1991009840A1 (en) | 1989-12-22 | 1991-07-11 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
US5223516A (en) | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
US5200426A (en) | 1990-08-14 | 1993-04-06 | Board Of Regents, The University Of Texas | Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents |
JPH04149166A (ja) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | 新規ケト酸アミド誘導体 |
CA2058797A1 (en) | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
SG43036A1 (en) | 1991-06-21 | 1997-10-17 | Thomae Gmbh Dr K | (S) (+) -2-ethoxy-4-[N-[1-(2-piperidino-phenyl)-3-methyl- 1-buthyl]aminocarbony methyl] - benzoic a cid |
GB9114006D0 (en) | 1991-06-28 | 1991-08-14 | Fujisawa Pharmaceutical Co | New propionamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
ES2100291T3 (es) | 1991-07-30 | 1997-06-16 | Ajinomoto Kk | Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos. |
EP0533130A1 (de) | 1991-09-19 | 1993-03-24 | Hoechst Aktiengesellschaft | 2-Hydroxymethylpyridine, die entsprechenden Pyridin-N-oxide und ihre Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung |
ZA927211B (en) | 1991-09-27 | 1993-03-24 | Merrell Dow Pharma | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE. |
US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
US5273990A (en) | 1992-09-03 | 1993-12-28 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives |
WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
JPH06234630A (ja) | 1992-12-17 | 1994-08-23 | Tanabe Seiyaku Co Ltd | 中性メタロエンドペプチダーゼ阻害剤 |
WO1994020457A1 (en) | 1993-03-02 | 1994-09-15 | G.D. Searle & Co. | N-acyl beta amino acid derivatives useful as platelet aggregation inhibitors |
JP3576193B2 (ja) | 1993-12-03 | 2004-10-13 | 第一製薬株式会社 | ビフェニルメチル置換バレリルアミド誘導体 |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5517996A (en) | 1994-04-21 | 1996-05-21 | Hitachi Medical Corporation | Ultrasonic diagnostic apparatus |
IT1270261B (it) | 1994-06-21 | 1997-04-29 | Zambon Spa | Derivati peptidici ad attivita' inibitrice delle metallopeptidasi |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
ES2145929T3 (es) | 1994-11-04 | 2000-07-16 | Santen Pharmaceutical Co Ltd | Nuevo derivado de 1,3-dialquil-urea que tiene un grupo hidroxilo. |
EP0798291B1 (en) | 1994-12-14 | 2002-09-11 | Santen Pharmaceutical Co., Ltd. | Novel 1,3-dialkylurea derivatives |
TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5550119A (en) | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
WO1998009940A1 (en) | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
FR2755135B1 (fr) | 1996-10-25 | 2002-12-27 | Inst Nat Sante Rech Med | Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
WO1998053817A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
WO1999026923A1 (en) | 1997-11-20 | 1999-06-03 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6169103B1 (en) | 1998-03-03 | 2001-01-02 | Warner-Lambert | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
JP4070357B2 (ja) | 1999-06-03 | 2008-04-02 | 花王株式会社 | 皮膚外用剤 |
GB2354440A (en) | 1999-07-20 | 2001-03-28 | Merck & Co Inc | Aryl amides as cell adhesion inhibitors |
US6521607B1 (en) | 1999-09-23 | 2003-02-18 | Pharmacia Corporation | (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6509330B2 (en) | 2000-02-17 | 2003-01-21 | Bristol-Myers Squibb Company | Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors |
JP2003530343A (ja) | 2000-04-12 | 2003-10-14 | ノバルティス アクチエンゲゼルシャフト | アルドステロンシンターゼインヒビター単体またはat1−レセプターアンタゴニストとの組み合わせの新規医薬使用 |
US7569724B2 (en) | 2000-09-29 | 2009-08-04 | Topotarget Uk Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
MXPA04006917A (es) | 2002-01-17 | 2004-12-06 | Novartis Ag | Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra. |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP4233353B2 (ja) | 2002-02-27 | 2009-03-04 | 田辺三菱製薬株式会社 | 医薬組成物 |
US20040063761A1 (en) | 2002-08-06 | 2004-04-01 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives |
EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
JP2006508970A (ja) | 2002-11-18 | 2006-03-16 | ノバルティス アクチエンゲゼルシャフト | イミダゾ[1,5a]ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法 |
US20040142379A1 (en) | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
EP1622886A2 (en) | 2003-04-30 | 2006-02-08 | The Institutes for Pharmaceutical Discovery, LLC | Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
JP2007500707A (ja) | 2003-07-29 | 2007-01-18 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | ビアリールヘテロ環状のアミン、アミドおよび硫黄−含有化合物、並びに該化合物の製造方法および使用方法 |
US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
ATE490241T1 (de) | 2004-05-28 | 2010-12-15 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
AR049126A1 (es) | 2004-05-28 | 2006-06-28 | Speedel Experimenta Ag | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. |
EP1749006A2 (en) | 2004-05-28 | 2007-02-07 | Speedel Experimenta AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
TW200611897A (en) | 2004-07-09 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
EP1778214A4 (en) | 2004-07-27 | 2010-04-14 | Glaxosmithkline Llc | NEW BIPHENYL COMPOUNDS AND THEIR USE |
WO2006015885A1 (en) | 2004-08-13 | 2006-02-16 | University College Dublin, National University Of Ireland, Dublin | Amino acid dehydrogenase-derived biocatalysts |
CA2588776A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Substituted amino carboxylic acids |
WO2006069096A1 (en) | 2004-12-20 | 2006-06-29 | Pharmacyclics, Inc. | Silanol derivatives as inhibitors of histone deacetylase |
MY146830A (en) | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
WO2007045663A2 (en) | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
US20080261958A1 (en) | 2005-11-08 | 2008-10-23 | Randy Lee Webb | Combination of Organic Compounds |
AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
CN101415803B (zh) | 2006-04-04 | 2012-10-24 | 大阳日酸株式会社 | 甲烷分离方法、甲烷分离装置以及甲烷利用系统 |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
US20100016379A1 (en) | 2006-05-15 | 2010-01-21 | Irm Llc | Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
AU2007290695A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
EP1903027A1 (en) | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
US8436035B2 (en) | 2006-12-18 | 2013-05-07 | Novartis Ag | Organic compounds |
BRPI0720383A2 (pt) | 2006-12-18 | 2015-06-16 | Novartis Ag | Derivados de 4-imidazolil-1,2,3,4-tetraidroquinolila e seu emprego como inibidores de aldosterona/11-beta-hidroxilase |
CN101578272A (zh) | 2006-12-18 | 2009-11-11 | 诺瓦提斯公司 | 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途 |
MY151993A (en) | 2007-01-12 | 2014-07-31 | Novartis Ag | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid |
TW200838501A (en) | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
EP2134720B1 (en) | 2007-03-29 | 2010-10-13 | Novartis AG | Heterocyclic spiro-compounds |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
CA2723671C (en) | 2007-05-10 | 2018-06-19 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
PT2295035T (pt) | 2007-11-06 | 2016-08-22 | Novartis Ag | Composições farmacêuticas de dupla acção com base em superestruturas de antagonista/bloqueador de receptores de angiotensina (arb) com inibidor da endopeptidase neutra (nep) |
CN101896470B (zh) | 2007-12-11 | 2013-04-10 | 施万制药 | 双重作用的苯并咪唑衍生物和其作为抗高血压药剂的用途 |
EP2070928A1 (en) | 2007-12-12 | 2009-06-17 | NERVIANO MEDICAL SCIENCES S.r.l. | 7-azaindol-3-ylacrylamides active as kinase inhibitors |
AR070176A1 (es) | 2008-01-17 | 2010-03-17 | Novartis Ag | Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis |
EP2334651A2 (en) | 2008-07-24 | 2011-06-22 | Theravance, Inc. | Dual-acting antihypertensive agents |
ES2602826T3 (es) | 2009-05-28 | 2017-02-22 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
MA33364B1 (fr) | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
RU2534619C2 (ru) | 2009-09-23 | 2014-11-27 | Чжэцзян Цзючжоу Фармасьютикл Ко., Лтд. | Способ получения n-ацилбифенилаланина |
JO2967B1 (en) * | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
-
2010
- 2010-11-14 JO JO2010398A patent/JO2967B1/en active
- 2010-11-16 US US12/947,029 patent/US8222286B2/en active Active
- 2010-11-18 SI SI201030649T patent/SI2501683T1/sl unknown
- 2010-11-18 ES ES14155848.6T patent/ES2598961T3/es active Active
- 2010-11-18 EA EA201200763A patent/EA021479B1/ru not_active IP Right Cessation
- 2010-11-18 NZ NZ599136A patent/NZ599136A/xx not_active IP Right Cessation
- 2010-11-18 PL PL10781884T patent/PL2501683T3/pl unknown
- 2010-11-18 AR ARP100104253A patent/AR079061A1/es not_active Application Discontinuation
- 2010-11-18 PT PT107818841T patent/PT2501683E/pt unknown
- 2010-11-18 KR KR1020127015833A patent/KR101460421B1/ko active IP Right Grant
- 2010-11-18 CA CA2780150A patent/CA2780150C/en not_active Expired - Fee Related
- 2010-11-18 EP EP14155848.6A patent/EP2735561B1/en active Active
- 2010-11-18 MY MYPI2012001258A patent/MY158299A/en unknown
- 2010-11-18 CN CN201080052316.5A patent/CN102666493B/zh not_active Expired - Fee Related
- 2010-11-18 PE PE2012000661A patent/PE20121311A1/es active IP Right Grant
- 2010-11-18 EP EP10781884.1A patent/EP2501683B1/en active Active
- 2010-11-18 AU AU2010320930A patent/AU2010320930B2/en not_active Ceased
- 2010-11-18 MX MX2012005813A patent/MX2012005813A/es active IP Right Grant
- 2010-11-18 IN IN2465DEN2012 patent/IN2012DN02465A/en unknown
- 2010-11-18 BR BR112012011977-0A patent/BR112012011977A2/pt not_active Application Discontinuation
- 2010-11-18 DK DK10781884.1T patent/DK2501683T3/da active
- 2010-11-18 JP JP2012538365A patent/JP5543609B2/ja not_active Expired - Fee Related
- 2010-11-18 RS RS20140355A patent/RS53422B/en unknown
- 2010-11-18 WO PCT/EP2010/067781 patent/WO2011061271A1/en active Application Filing
- 2010-11-18 ES ES10781884.1T patent/ES2481890T3/es active Active
- 2010-11-18 MA MA34949A patent/MA33886B1/fr unknown
- 2010-11-19 TW TW099140059A patent/TWI481598B/zh not_active IP Right Cessation
- 2010-11-22 UY UY0001033044A patent/UY33044A/es not_active Application Discontinuation
-
2012
- 2012-03-19 ZA ZA2012/02018A patent/ZA201202018B/en unknown
- 2012-03-21 TN TNP2012000125A patent/TN2012000125A1/en unknown
- 2012-04-18 US US13/449,357 patent/US8377978B2/en active Active
- 2012-04-19 IL IL219314A patent/IL219314A0/en not_active IP Right Cessation
- 2012-05-08 CR CR20120237A patent/CR20120237A/es unknown
- 2012-05-10 CO CO12076695A patent/CO6540001A2/es unknown
- 2012-05-16 HN HN2012001037A patent/HN2012001037A/es unknown
- 2012-05-18 GT GT201200153A patent/GT201200153A/es unknown
- 2012-05-18 CL CL2012001298A patent/CL2012001298A1/es unknown
- 2012-06-18 EC ECSP12011978 patent/ECSP12011978A/es unknown
- 2012-10-26 HK HK12110737.3A patent/HK1170475A1/xx not_active IP Right Cessation
- 2012-12-05 US US13/705,475 patent/US8642635B2/en active Active
-
2013
- 2013-12-02 US US14/093,956 patent/US8877786B2/en active Active
-
2014
- 2014-05-08 JP JP2014096844A patent/JP2014167015A/ja active Pending
- 2014-07-18 HR HRP20140691AT patent/HRP20140691T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201200153A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
PA8842101A1 (es) | Heteroarilos sustituidos | |
GT201400034A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
CO6670585A2 (es) | Promotores de apotosis n-acilsufonamidas | |
CR20120158A (es) | Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso. | |
UY32626A (es) | Inhibidores de beta-lactamasa | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
GT201100303A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
PE20160841A1 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
CO6501191A2 (es) | Medio de cultivo celular para expresión de la proteina adamts | |
CL2012000590A1 (es) | Proceso para preparar w-transaminasa (r)-selectiva. | |
ECSP12011793A (es) | Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
ECSP14013302A (es) | Composiciones de yodo-povidona estable | |
GT201200084A (es) | Antitransparente que reduce/elimina la decoloración amarilla en las prendas de vestir | |
BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
NI201400042A (es) | 2 - tiopirimidinonas | |
UY32767A (es) | Métodos para tratar nvpa y nvpo con composiciones de ondansetrón de liberación prolongada | |
CO6331434A2 (es) | Nuevos compuestos | |
ECSP11011486A (es) | Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente | |
AR067140A2 (es) | Nuevo procedimiento de tratamiento de frutas o legumbres mediante el ion fosforoso y las composiciones correspondientes | |
BR112012017393A2 (pt) | derivados de 2,5,7-oxazolpirimidina substituída | |
GT201300267A (es) | Isoxazolinas como agentes terapéuticos |